Stem cells · Lesson 8 of 8 · 3 min

How do published stem cell studies select patients?

Who is enrolled shapes what a stem cell study can show. This guide covers how published MSC research frames disease stage, phenotype and tissue type.

A researcher looking into a microscope

Key takeaways.

  • Study participant selection is framed around four domains, starting with disease characteristics.
  • In published osteoarthritis studies, the most favourable outcomes were reported at Kellgren-Lawrence grade 2 to 3.
  • The inflammatory osteoarthritis phenotype is hypothesised to be more responsive to MSC immunomodulation.
  • Chronic tendinopathy is a failed healing response, not an inflammatory condition.
  • The ACL heals poorly because it sits inside the synovial environment with poor blood supply.
  • These are research findings. MSC therapy for osteoarthritis is not FDA-approved.

Four assessment domains

The course frames participant selection around four domains: disease characteristics, patient factors, treatment history, and expectations and goals.

Disease characteristics covers the biological nature of the condition. That includes disease stage, tissue quality and regenerative potential. It is the domain the published literature says most about.

Osteoarthritis: stage and phenotype

Osteoarthritis is the most commonly studied application of mesenchymal stem/stromal cell (MSC) research. In published studies, researchers have reported the most favourable outcomes at Kellgren-Lawrence grade 2 to 3, which is moderate disease. The stated rationale is that very early disease shows little measurable change, while advanced disease leaves insufficient tissue.

Phenotype is also studied. The inflammatory phenotype shows synovial inflammation and elevated inflammatory markers. Researchers hypothesise that it may be more responsive to MSC immunomodulation than the mechanical, metabolic or post-traumatic phenotypes.

Soft tissue: know the pathology

Chronic tendinopathy is different from acute tendinitis. It is a failed healing response with disorganized collagen and neovascularization, not inflammation. The suffix "-opathy" signals a degenerative process.

Ligaments differ too. The ACL has limited natural healing capacity compared with the MCL. It sits within the synovial environment with poor blood supply, and its location inside the joint restricts access to healing factors.

Read these as research findings

These points describe how studies were designed and what they reported. They are not treatment criteria. MSC therapy for osteoarthritis is not FDA-approved, and stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses that clinics market.

Educational content for healthcare professionals. Not a treatment recommendation. Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses most clinics offer.

Stem cells: 0 of 8 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • The full four-domain assessment framework
  • Outcome measures and how to judge study quality
  • Evidence by condition, including neurological and aesthetic research
  • Administration routes used in published research
  • Setting expectations with patients

Common questions.

Which osteoarthritis grade has been reported to do best in MSC studies?
Published studies have reported the most favourable outcomes at Kellgren-Lawrence grade 2 to 3. These are research findings, and MSC therapy for osteoarthritis is not FDA-approved.
Why does osteoarthritis phenotype matter in MSC research?
Researchers hypothesise that the inflammatory phenotype may be more responsive to MSC immunomodulation. This is a hypothesis in study settings, not an established result.
How is tendinopathy different from tendinitis?
Chronic tendinopathy is a failed healing response with disorganized collagen and neovascularization. It is a degenerative process, not an inflammatory one.

Sources

  • Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: A randomized double-blind placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504-13.
  • Pers YM, Rackwitz L, Ferreira R, Pullig O, Delfour C, Barry F, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial. Stem Cells Transl Med. 2016;5(7):847-56.
  • Freitag J, Bates D, Boyd R, Shah K, Barnard A, Huguenin L, et al. Mesenchymal stem cell therapy in the treatment of osteoarthritis: Reparative pathways, safety and efficacy - a review. BMC Musculoskelet Disord. 2016;17:230.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.